<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04525066</url>
  </required_header>
  <id_info>
    <org_study_id>1020322</org_study_id>
    <nct_id>NCT04525066</nct_id>
  </id_info>
  <brief_title>Phonosurgical Augmentation After Laser Resection of Early Glottic Carcinoma</brief_title>
  <official_title>Injection Thyroplasty During Transoral Laser Microsurgery for Early Glottic Cancer: Single-blinded Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ayhman Al Afif</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nova Scotia Health Authority</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nova Scotia Health Authority</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives: Transoral Laser Microsurgery (TLM) is widely used in for treating T1/T2 glottic&#xD;
      cancers. Hyaluronic acid (HA) is a safe and commonly-used injectable in vocal cord&#xD;
      augmentation. We report on the results of our single-blinded, randomized-controlled trial&#xD;
      (RCT) investigating the impact of intra-operative HA injection on voice outcomes in early&#xD;
      glottic cancer.&#xD;
&#xD;
      Methods: Patients with T1/T2 glottic cancers were randomized to the treatment group (n=14)&#xD;
      receiving HA injection to the unaffected cord during TLM; or the control group, receiving no&#xD;
      injection (n=16). All patients had a Voice Handicap Index-10 (VHI-10) questionnaire and a&#xD;
      Maximum Phonation Time (MPT) measurement preoperatively and at 3, 12 and 24 months&#xD;
      post-operatively. Mean change in VHI-10 and MPT, between pre-operative and post-operative&#xD;
      time points, and between the time points, were compared. Survival estimates were also&#xD;
      calculated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 13, 2013</start_date>
  <completion_date type="Actual">August 13, 2018</completion_date>
  <primary_completion_date type="Actual">August 13, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Voice Outcome</measure>
    <time_frame>Change at 3 months post-operatively compared to baseline.</time_frame>
    <description>Voice Handicap Index-10 Scores</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Voice Outcome</measure>
    <time_frame>Changes at 12 months post-operatively compared to baseline.</time_frame>
    <description>Voice Handicap Index-10 Scores</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Voice Outcome</measure>
    <time_frame>Changes at 24 months post-operatively compared to baseline.</time_frame>
    <description>Voice Handicap Index-10 Scores</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Voice Outcome</measure>
    <time_frame>Changes at 3 months post-operatively compared to baseline.</time_frame>
    <description>Maximum Phonation Time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Voice Outcome</measure>
    <time_frame>Changes at 12 months post-operatively compared to baseline.</time_frame>
    <description>Maximum Phonation Time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Voice Outcome</measure>
    <time_frame>Changes at 24 months post-operatively compared to baseline.</time_frame>
    <description>Maximum Phonation Time</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>24 months post-augmentation</time_frame>
    <description>Kaplan-Meier Survival Analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>24 months post-augmentation</time_frame>
    <description>Kaplan-Meier Survival Analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence-free survival</measure>
    <time_frame>24 months post-augmentation</time_frame>
    <description>Kaplan-Meier Survival Analysis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Head and Neck Neoplasms</condition>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <condition>Voice Disorders</condition>
  <condition>Laryngeal Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment Group - Receiving Hyaluronic Acid Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized group of patients receiving hyaluronic acid injection into the glottis during transoral laser microsurgery for early glottic cancer.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group - Not Receiving Hyaluronic Acid Injection</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Randomized group of patients not receiving hyaluronic acid injection into the glottis during transoral laser microsurgery for early glottic cancer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyaluronic acid</intervention_name>
    <description>Patients in the treatment group received hyaluronic acid injection into the unaffected vocal cord intra-operatively during transoral laser microsurgery for early glottic cancer.</description>
    <arm_group_label>Treatment Group - Receiving Hyaluronic Acid Injection</arm_group_label>
    <other_name>Hyaluronic Acid Laryngoplasty</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No Hyaluronic Acid Injection Injection</intervention_name>
    <description>Patients in the placebo group did not receive hyaluronic acid injection into the unaffected vocal cord intra-operatively during transoral laser microsurgery for early glottic cancer.</description>
    <arm_group_label>Control Group - Not Receiving Hyaluronic Acid Injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females&#xD;
&#xD;
          -  18 years of age or older with a biopsy-proven T1a, T1b or T2 glottic SCC&#xD;
&#xD;
          -  Lesion amenable to CO2 TLM resection.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous radiotherapy to the head and neck.&#xD;
&#xD;
          -  Palpable, or radiographic, pathological lymphadenopathy.&#xD;
&#xD;
          -  Allergy, or sensitivity, to HA or components of the injectable.&#xD;
&#xD;
          -  Neurological disorder affecting phonation, such as multiple sclerosis or stroke.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 11, 2020</study_first_submitted>
  <study_first_submitted_qc>August 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2020</study_first_posted>
  <last_update_submitted>August 20, 2020</last_update_submitted>
  <last_update_submitted_qc>August 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Nova Scotia Health Authority</investigator_affiliation>
    <investigator_full_name>Ayhman Al Afif</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Laryngeal Neoplasms</mesh_term>
    <mesh_term>Voice Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

